Safety and efficacy of non-reduced use of caspofungin in patients with Child-Pugh B or C cirrhosis: a real-world study.

Background And Purpose: The need for dose adjustment of caspofungin in patients with hepatic impairment is controversial, especially for those with Child-Pugh B or C cirrhosis. The purpose of this study was to investigate the safety and efficacy of standard-dose caspofungin administration in Child-Pugh B and C cirrhotic patients in a real-world clinical setting.

Patients And Methods: The electronic medical records of 258 cirrhotic patients, including 67 Child-Pugh B patients and 191 Child-Pugh C patients, who were treated with standard-dose of caspofungin at the Second Affiliated Hospital of Chongqing Medical University, China, from March 2018 to June 2023 were reviewed retrospectively.

Fabrication and Microstructure of ZnO/HA Composite with In Situ Formation of Second-Phase ZnO.

Nanometer hydroxyapatite (n-HA) powders were synthesized by the chemical precipitation method, and a novel ZnO/HA composite, which consisted of second-phase particles with different sizes and distributions, was successfully fabricated. ZnO/HA composites were prepared by using powder sintering with different Zn contents and a prefabrication pressure of 150 MPa. Microstructure and local chemical composition were analyzed by a scanning electron microscope (SEM) and energy-dispersive spectrometer (EDS), respectively.